The CRISPR/Cas9 technology is a powerful tool for gene editing (1-3).
The CRISPR/Cas9 technology is a powerful tool for gene editing (1-3).
Application of this technology to primary cells is still in its initial phase, but promises to accelerate research. In many instances, such as the primary hematopoietic cells studied here, high knockout efficiencies are essential for studying gene function, as the limited life span of the cells often does not allow for selection and expansion of knockout clones prior to in vitro experiments. Moreover, screens that are based on readouts that do not affect survival require high knockout efficiencies to identify true positive hits. The two most decisive factors for high CRISPR/Cas9 knockout efficiencies are sufficient nuclear Cas9 levels and the selection of potent sgRNAs (4, 5) . To overcome the requirement of Cas9 delivery to primary cells, transgenic mice expressing Cas9 and GFP from the Rosa26 locus have been generated (6; a related approach, targeting the hematopoietic system, has been lentiviral Cas9 transduction into hematopoietic stem cells, ref. 7) . While primary dendritic cells of these mice have been successfully used for functional screening in vitro (6, 8) , their lymphocytes express only low levels of GFP, and their use in CRISPR-mediated screens has not been reported so far. In addition, these mice were not generated on a pure C57BL/6 background. We thus generated a new C57BL/6 Cas9-transgenic line with an improved Cas9 expression cassette (9). As we were interested in small-scale screening, a key consideration was to use only few, but reliable sgRNAs without the necessity of sgRNA-testing experiments prior to screening. Previous studies have shown large variations in sgRNA efficiencies (8, (10) (11) (12) . Multiple sgRNA design programs have been developed, but none of them combines all the criteria that we developed in-lab to reach optimal sgRNA activity and specificity, including on-target efficiency, genome-wide off-target predictions taking into account the impact of mismatch-type and -position, targeting of all isoforms of genes, and conservation of functional secondary structure of the sgRNA (13). We thus developed a new sgRNA design tool that selects sgRNAs having high specificity, high on-target efficiency and intact secondary structure important for the recognition by Cas9. Combining this new program with our Cas9 transgenic C57BL/6 mice, we established an easy and robust screening method to study gene function in primary hematopoietic (and likely other) cells with high signal-to-noise ratio.
Results

Design of specific and efficient sgRNAs
Coding genes typically contain hundreds of protospacer adjacent motif (PAM) sequences, allowing for a wide choice among possible sgRNAs. To design the most specific and efficient sgRNAs to target a gene or set of genes, we implemented our sgRNA design rules in a new tool that we termed CrispRGold. CrispRGold first projects the coding sequences (CDS) of the different isoforms of a gene to a single 'minimal CDS', in order to identify sgRNAs that would target most or all isoforms of that gene. For each sgRNA candidate, the position in the minimal CDS is stored and the sgRNA is aligned to the genome using the Burrows-Wheeler Aligner (BWA) (14) to identify offtarget sites. Based on the quantitative measurement of off-target site activity (15), we defined a type-and position-dependent mismatch-penalty matrix, such that the sum of mismatch-penalties (or mutation distance) for the various off-target sites would inversely correlate with the frequency of detected offtarget site activities ( Fig. 1A and B) . This mismatch penalty matrix especially weighs the increased impact of mismatches close to the 3'-end of the sgRNA and the decreased relevance of mutations causing wobble base pairing.
CrispRGold uses this matrix to calculate the risk of each individual predicted off-target site genome-wide for a given sgRNA, sorts these sites according to their risk, and attributes a global off-target risk (or specificity score) to each sgRNA based on the three off-target sites with the highest risk. In addition, CrispRGold computes sgRNA-intrinsic properties, such as the GC-content and the folding energy between the targeting sequence and the scaffold-RNA of the sgRNA (16). A high binding energy between the targeting sequence and the scaffold may alter the secondary structure of the sgRNA and potentially disturb recognition of the sgRNA by Cas9 or binding of the targeting sequence to the DNA (Fig. 1C) . Finally, CrispRGold goes through iterative loops of decreasing stringency to find the required number of sgRNAs per gene or sequence. In each loop, sgRNAs are prioritized according to their specificity (Fig. 1D ).
Characterization of a new Cas9 transgenic mouse line
In the mice created by Platt et al. (6) (hereafter called R26-Cas9p2aGFP), the Cas9 protein is fused to eGFP via a self-cleaving P2A peptide. In our Rosa26-LSL-Cas9iGFP mice, generated by CRISPR-mediated editing of C57BL/6 zygotes, Cas9 is also expressed from the Rosa26 locus in a Cre-dependent manner, but with the Cas9 coding sequence linked to eGFP via an internal ribosomal entry site (IRES) (9). To apply the CRISPR/Cas9 technology to primary immune cells, we generated Cas9-transgenic mice with ubiquitous expression of Cas9 by crossing Rosa26-LSL-Cas9iGFP with Cre-deleter mice (Fig. 1E) . We then evaluated the expression of Cas9 in the resulting R26- Cas9iGFP/+ and control mice, indicating that the expression of Cas9iGFP is not toxic to any of these cell types (Fig. 1H) . GFP levels in R26-Cas9iGFP/+ mice were higher than in R26-Cas9p2aGFP/+ mice (6), likely due to the presence of the IRES instead of the P2A peptide between Cas9 and GFP ( Fig. S2A and B) . To confirm that Cas9 is indeed present in the GFP + cells, we performed western blotting on splenic B cells that were activated in vitro and on BM-derived macrophages (BMDM). In both cases, we detected high levels of Cas9 protein (Fig. S3A) . Moreover, Cas9 was localized in the nucleus in the BMDM (Fig. S3B) . Thus, primary immune cells of R26-Cas9iGFP/+ animals express high levels of GFP and nuclear Cas9 to nontoxic levels, allowing for genome editing and easy discrimination of Cas9 + and Cas9 -cells in subsequent experiments.
Efficient CRISPR/Cas9-mediated mutagenesis in primary immune cells
To assess the knockout efficiency of the sgRNAs designed by CrispRGold in primary immune cells, we first selected 12 genes encoding B cell surface markers and designed 2 sgRNAs per gene (Fig. S4A) CrispRGold. To confirm that these high knockout efficiencies are not unique to B cells, we performed a similar experiment using primary T cells that we activated with anti-CD3 and anti-CD28 (Fig. S5A ). Four days after transduction with retroviral particles encoding sgRNAs against CD44, about 50% of the cells showed a complete knockout of CD44 (Fig. 2D) . Finally, to determine if we reach similarly high knockout frequencies in quiescent primary myeloid cells, we differentiated bone marrow cells into resting BMDMs using M-CSF and transduced them with lentiviral vectors expressing sgRNAs targeting CD64 and CD14 (Fig. S5B ). Four days after transduction, 40-80% of the cells showed a knockout of the targeted genes ( Fig. 2E and Fig. S5C ).
Thus, primary immune cells of R26-Cas9iGFP/+ mice are suitable for CRISPR/Cas9-mediated genome editing, and CrispRGold designs reliably highly efficient sgRNAs. In addition to the intrinsic properties of sgRNAs, the on-target dosage of sgRNA/Cas9 complexes is essential for efficient mutagenesis. The lower GFP levels in lymphocytes of R26-Cas9p2aGFP/+ mice (6) suggested that they have lower levels of Cas9 than the R26-Cas9iGFP/+ mice here described. To compare the impact of Cas9-dosage on knockout efficiency, we thus repeated the experiment depicted in Fig. 2A Fig. S3C ), consistent with lower Cas9 levels in these cells (Fig.   S3D ). Thus, the combination of optimal sgRNAs and high levels of Cas9 in primary cells of R26-Cas9iGFP/+ mice led to the high knockout efficiencies observed in primary cells isolated from these animals.
Robust inactivation of transcription factors known to be important for B cell differentiation
Extending the analysis to transcription factors (TFs), we selected 5 TFs, , Irf4, Myc, Xbp1, and Pou2af1 , that are known to be important for B cell survival, proliferation and differentiation (18-24) (Fig. S6A ). We designed 3 sgRNAs per TF ( 
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Identification of novel genes important for B cell activation and plasma cell differentiation
Benefitting from the robustness of our system and the consistently high knockout frequencies, we performed a small-scale screen to identify novel genes important for B cell proliferation and terminal differentiation. Based on a microarray analysis of B cells and plasma cells isolated from immunized mice, we selected 83 candidate genes up-regulated during plasma cell differentiation in vivo (Fig. S7 ). We designed one sgRNA against each of these genes and 13 control genes. We then performed the same experiment as before in a 96-well system, using the percentage of GFP + and CD138 
Discussion
We provide a new and flexible sgRNA design tool that reliably identifies highly specific and efficient sgRNAs for a given set of genes or DNA sequences.
CrispRGold can also be used for other organism, and will be available on a web platform. Primary cells of R26-Cas9iGFP/+ mice express high levels of GFP and Cas9 to non-toxic levels, allowing for efficient CRISPR-mediated gene editing and the use of GFP -internal controls. We show that these tools can be combined in an easy and robust screening assay of CRISPR mutagenesis in primary hematopoietic cells, and identify novel genes important for B cell activation and terminal differentiation. The same approach
can be easily applied to other types of primary cells.
Methods
Mice
Cas9 knock-in mice were reported previously (9). Briefly, we knocked a 
CrispRGold
Minimal CDS (minCDS) are generated based on the refseq tables (mm9). 
96-well cloning approach
The MSCV_hU6_CcdB_PGK_Puro_T2A_BFP vector was generated by cloning the PCR-amplified hU6-BbsI-CcdB-BbsI-gRNA fragment into the SalI deep-well plates containing 1.5ml LB liquid medium and sealed with PCR seals (Thermo Scientific). These plates were cultured for 12 h then split into 2 new 96 deep-well plates and further cultured for 10-12h. Bacteria were collected by centrifugation at 4000 rpm for 1 min and plasmids were isolated using the NucleoSpin" 96 plasmid core kit (Macherey-Nagel).
Cell culture
Retroviral Plat-E packaging cells were maintained in DMEM (Gibco) supplied with 10% FCS (Gibco), 2mM L-Glutamine (Gibco), and 2mM Sodium Pyruvate (Gibco). 40LB feeder cells, producing BAFF and CD40L, were previously generated by Nojima et al(17) and maintained in completed DMEM medium.
To prepare the feeder layer, 40LB feeder cells were irradiated with 12G# and plated at 5x10 4 cells/cm. Naïve B cells were isolated from the spleen of R26-Cas9iGFP/+, R26-Cas9p2aGFP/+ or C57BL/6 mice by depletion of CD43 + cells using CD43 microbeads (Miltenyi Biotec). Resting B cells were plated at 6 cells/ml in DMEM (Gibco) supplied with 10% FCS (Gibco), 2mM LGlutamine, 2mM Sodium Pyruvate, 2mM HEPES (Gibco), 1x NAA (Gibco), beta-mercaptoethanol (Sigma), and 10µg/ml Gentamicin (Lonza). Cas9
(GFP + )-expressing B cells were mixed wildtype (GFP -) B cells and stimulated with anti-CD40 antibody (Biolegend) and IL-4 (Perprotech) for 48h before retroviral transduction.
High-throughput retroviral production
Plat-E cells were plated at 2.2x10 4 cells/100µl medium in each well of 96-well plates at day 0. 1 day later, the cells were transfected with 100ng DNA using 
FACS analysis and sorting
For FACS analysis, single cell suspensions were prepared from the bone marrow, spleen, peritoneal cavity and mLN from R26-Cas9iGFP/+, R26- . Gene set used for the small-scale screen. Total RNA was isolated from follicular B, GC and plasma cells that were isolated from the spleen and BM of immunized animals. Microarrays were performed and data were normalized prior to analysis. The heat-map shows the expression levels of the selected genes with differential expression in the plasma cell populations. Fig. S8 . Small scale-CRISPR-mediated screening to detect novel genes important for B cell activation and plasma cell differentiation. (A) Scheme of the high-throughput 96 well-based screening approach. One sgRNA was designed for each gene of interest. Each sgRNA was separately cloned into a retroviral vector. The cloning, retrovirus production and transduction of B cells was performed in 96 well plates. The transduced cells were selected with Puromycin. Survival/proliferation was analyzed based on monitoring the percentage of GFP + Cas9-expressing B cells at different time points. The fold changes were calculated by comparing to the percentage of GFP + cells at day 2, allowing for the identification of repressor or enhancer genes. The plasmablast assay was based on the normalization of GFP + -derived CD138 + plasmablasts to GFP --derived CD138 + plasmablasts. (B) Diagram showing the screen set and identification of important genes for survival and proliferation (middle, top) and plasma cell differentiation (middle, bottom). 22 genes were crucial for activated B cell survival and proliferation, and 8 genes were essential for plasma cell generation.10 genes were essential for both survival/proliferation and differentiation. 
